
    
      Part A of the study is an open-label design with dosing of SAGE-217 for 14 days.

      Part B of the study is a randomized, double-blind, parallel-group, placebo-controlled design.
      Eligible participants were randomized to SAGE-217 or placebo for 14 days.
    
  